Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
1.89M | 19.94M | 16.40M | 0.00 | 0.00 | Gross Profit |
1.89M | -18.96M | 13.89M | -735.00K | -777.00K | EBIT |
-73.59M | -40.50M | -56.06M | -50.09M | -22.40M | EBITDA |
-64.05M | -32.47M | -51.30M | -49.25M | -14.26M | Net Income Common Stockholders |
-70.52M | -37.37M | -51.56M | -49.77M | -14.94M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
112.22M | 134.34M | 129.31M | 157.53M | 92.57M | Total Assets |
126.93M | 174.83M | 160.25M | 179.25M | 96.40M | Total Debt |
10.99M | 51.92M | 14.68M | 15.66M | 2.54M | Net Debt |
-101.22M | -82.42M | -114.63M | -141.87M | -90.03M | Total Liabilities |
53.54M | 63.46M | 37.91M | 26.46M | 148.26M | Stockholders Equity |
73.39M | 111.37M | 122.34M | 152.79M | -51.86M |
Cash Flow | Free Cash Flow | |||
-56.44M | -33.38M | -44.21M | -43.37M | -19.18M | Operating Cash Flow |
-56.19M | -32.61M | -40.60M | -42.88M | -18.62M | Investing Cash Flow |
-254.00K | -769.00K | -3.61M | -498.00K | -560.00K | Financing Cash Flow |
13.08M | 58.43M | 15.91M | 109.43M | 93.86M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
48 Neutral | $1.09B | ― | -57.48% | ― | 13698.99% | 31.46% | |
46 Neutral | $50.42M | ― | -273.36% | ― | 194.23% | 45.50% | |
45 Neutral | $538.30M | 49.63 | 3.73% | ― | 188.64% | ― | |
42 Neutral | $90.54M | ― | -54.21% | ― | -78.55% | -0.92% | |
41 Neutral | $297.65M | ― | -55.13% | ― | -86.25% | 36.10% | |
36 Underperform | $39.02M | ― | -76.33% | ― | -90.55% | -55.06% |
On February 19, 2025, Derek DiRocco, M.D., announced his resignation from the Board of Directors of Werewolf Therapeutics, effective at the company’s 2025 annual meeting of stockholders. His departure was not due to any disagreement with the company. Concurrently, Anil Singhal, Ph.D., was appointed as a new director and member of the Audit Committee. Dr. Singhal brings over three decades of experience in the biopharmaceutical industry, having previously led Trishula Therapeutics and Adicet Bio. His appointment is expected to strengthen Werewolf Therapeutics’ leadership and strategic direction, potentially impacting its market positioning and stakeholder interests.